Noticias de ELVN_US

Mercado

Noticias del mercado

Últimas noticias sobre ELVN_US — 82 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: ELVN_US ✕ 82 resultados
14/10/2026 ELVN_US — PR Newswire
Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year

/PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...

12/10/2026 ELVN_US — Investing.com
Enliven Therapeutics director Scott Garland sells $606k in stock By Investing.com
12/10/2026 ELVN_US — Investing.com
Form 4 Enliven Therapeutics Inc For: 12 October By Investing.com
12/10/2026 ELVN_US — Investing.com
Enliven Therapeutics director Scott Garland sells $606k in stock By Investing.com
12/10/2026 ELVN_US — Investing.com
Form 4 Enliven Therapeutics Inc For: 12 October By Investing.com
12/10/2026 ELVN_US — Investing.com
Enliven Therapeutics director Scott Garland sells $606k in stock
12/10/2026 ELVN_US — Investing.com
Form 4 Enliven Therapeutics Inc For: 12 October By Investing.com
12/10/2026 ELVN_US — Investing.com
Enliven Therapeutics director Scott Garland sells $606k in stock By Investing.com
12/10/2026 ELVN_US — Investing.com
Enliven Therapeutics director Scott Garland sells $606k in stock By Investing.com
11/10/2026 ELVN_US — Stock Traders Daily
The Technical Signals Behind (ELVN) That Institutions Follow

Price-action only: Enliven Therapeutics Inc. (ELVN) movements set the tone for institutional models. The Technical Signals Behind (ELVN) That Institutions Follow

10/10/2026 ELVN_US — dars.gov.et
Enliven Therapeutics (ELVN) Edges Up 0.86% to $40.98, Sitting at the Midpoint of Its Recent Range - McClellan Summation
10/10/2026 ELVN_US — https://www.siam.in/
Enliven Therapeutics (ELVN) Edges Up 0.86% to $40.98, Sitting at the Midpoint of Its Recent Range - Volatility Skew
07/10/2026 ELVN_US — MarketScreener
Enliven Therapeutics Reaches Realignment With FDA on Final Design of Relcobatinib's Phase 3 Trial
06/10/2026 ELVN_US — Investing.com
Enliven gets FDA alignment on phase 3 trial for leukemia drug
06/10/2026 ELVN_US — Investing.com
Enliven gets FDA alignment on phase 3 trial for leukemia drug
06/10/2026 ELVN_US — MarketScreener
Enliven Therapeutics Announces FDA Alignment On ENABLE-2 Pivotal Phase 3 Trial Design For Relcobatinib In Previously Treated Chronic Myeloid Leukemia
06/10/2026 ELVN_US — PR Newswire
Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia

/PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...

06/10/2026 ELVN_US — Stock Titan
The FDA aligned with Enliven on a leukemia trial design for about 450 adults, with a start planned before year-end.

Se comparará relcobatinib 80 mg al día con otros tres fármacos; La respuesta molecular principal se medirá en la semana 24 y el inicio del ensayo está previsto antes de fin de año.

05/10/2026 ELVN_US — Stock Titan
After exercising options at $15.47, Enliven Therapeutics (ELVN) director sells 13,000 shares.
03/10/2026 ELVN_US — Webull
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Página 2 de 5